FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGE	S IN BENE	FICIAL O	WNERSH	ΙP

l	OMB APPROVAL									
l	OMB Number:	3235-0287								
l	Estimated average burde	en								
	hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Wolchko J Scott				2. Issuer Name and Ticker or Trading Symbol FATE THERAPEUTICS INC [FATE]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
			-		TITLE	7111	101100	<u> </u>	iii j		X Directo	r		10% Ow	ner		
(Last) (First) (Middle)			3.	Date of Earliest Transaction (Month/Day/Year)						X Officer below)	(give title		Other (sp below)	ecify			
C/O FATE THERAPEUTICS, INC.;				0	07/18/2018						President and CEO						
3535 GENERAL ATOMICS COURT #200				L													
				— 4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) SAN DIE	EGO C.	A	92121									,	led by One	Report	ting Person		
				_						Form fi Person	Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3) 2. Transa Date (Month/D			•	2A. Deemed Execution Date, if any (Month/Day/Year		Code (Instr.		ed (A) or str. 3, 4 and	5. Amour Securitie Beneficia Owned F Reported	s Illy ollowing	Form:	n: Direct II r Indirect E estr. 4) C	7. Nature of ndirect Beneficial Dwnership Instr. 4)				
								Code	Amount	(A) o	r Price	Transacti (Instr. 3 a	ion(s)		"	1150.4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	or Exercise (Month/Day/Year) if any		Execution Date,	Code (Instr.		Derivative		Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	ily	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	5.1(3)			
Stock Option (right to buy)	\$11.03	07/18/2018		A		450,000		(1)	07/17/2028	Common Stock	450,000	(2)	450,00	00	D		

Explanation of Responses:

- 1. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on August 18, 2018 such that this option is fully exercisable on July 18, 2022.
- 2. Not applicable.

Remarks:

/s/ Cindy R. Tahl, as Attorney-

07/20/2018

in-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.